Rankings
▼
Calendar
RXRX FY 2021 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RXRX
Recursion Pharmaceuticals, Inc.
$2B
FY 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$10M
+193.0% YoY
Gross Profit
$10M
100.0% margin
Operating Income
-$183M
-1827.8% margin
Net Income
-$186M
-1864.8% margin
EPS (Diluted)
$-1.05
Cash Flow
Operating Cash Flow
-$159M
Free Cash Flow
-$198M
Stock-Based Comp.
$15M
Balance Sheet
Total Assets
$610M
Total Liabilities
$67M
Stockholders' Equity
$543M
Cash & Equivalents
$285M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$10M
$3M
+193.0%
Gross Profit
$10M
$3M
+193.0%
Operating Income
-$183M
-$85M
-116.0%
Net Income
-$186M
-$87M
-114.3%
← Q4 2020
All Quarters
Q1 2021 →